A Novel Alpha-thalassemia Nonsense Mutation in HBA2: C.382 A > T globin Gene

Mohammad Hamid PhD1,2, Hanieh Bokharaei Merci MSc1, Hamid Galehdari PhD3, Ali Hossein Saberi PhD2,3, Bijan Kaikhaei MD4, Marziye Mohammadi-Anaei BSc2, Ahmad Ahmadzadeh MD5

Abstract

In this study, a new alpha thalassemia mutation on the α2-globin gene is reported. This mutation resulted in a Lys > stop codon substitution at position 127 which was detected in four individuals (three males and one female). DNA sequencing revealed this mutation in unrelated persons in Khuzestan province, Southwestern Iran of Lor ethnicity. This mutation caused no severe hematological abnormalities in the carriers. From the nature of substituted residues in α2-globin, it is widely expected that this mutation leads to unstable and truncated protein and should be detected in couples at risk for α-thalassemia.

Keywords: Iran, α-globin gene mutation, α-thalassemia

Introduction

Alpha thalassemia, the most common inherited disorder of hemoglobin in the world, is caused by deletion and/or mutation of ≥ 1 of the four alpha-globin genes.1-2 The Iranian population is composed of a mixture of different ethnic groups and the most frequent lesion reported so far is the -α3.7 mutation.2 Khuzestan province located in southwestern Iran comprises different ethnicities including Arab, Lor and Persian. The -α3.7 single gene deletion was the most frequently identified variant, representing 62.6% of the total in Khuzestan province.3 In the present study, we describe heterozygosity for a new nonsense mutation on the α2 globin gene.

Materials and Methods

This study included individuals referred to the Narges Prenatal Diagnostics and Medical Genetics Laboratory as part of a national program for prevention of thalassemia. The red blood cell indices and hemoglobin analysis were carried out according to standard methods. After obtaining written informed consent, molecular studies were conducted on genomic DNA isolated from peripheral blood cells by salting-out procedure.4 For identifying α-thalassemia genotype, investigation of common Mediterranean α-globin gene deletions (-α7, -α4.2 -α20.5 and --MED) was performed by Gap-PCR as described previously;5 the entire α and β-globin genes were amplified and DNA sequenced, ABI -3130 (Applied Biosystems, Foster City, CA, USA).

Results

Hemoglobin (Hb) analysis by applying cellulose acetate electrophoresis at alkaline pH (8.4 – 8.6) did not indicate any abnormal Hb fraction. Sequencing of the α-globin gene of subjects detected a novel mutation α2 cd127 which results in premature stop codon in the third exon of α2-globin genes (Figure 1). The mutation alpha2 [α127 (H10) Lys > stop] was detected in four individuals (three males and one female) showing a phenotype of moderate anemia, mild microcytosis and moderate hypochromia. Subjects were unrelated of Lor ethnicity from Khuzestan province. The hematological and molecular features of this mutation in carrier individuals are summarized in Table 1.

Discussion

The A > T mutation at codon 127 of the α2-globin genes leads to a substitution of Lysine by a stop codon which in heterozygosity shows no detrimental impact in carriers. Nonsense mutations occur when a premature stop codon is introduced in the DNA sequence, resulting in a shorter and unfinished protein product. The truncated protein is not able to form a stable dimer and is degraded by the proteolytic pathway.4 However, we can also expect this mutation to result in synthesis of unstable truncated proteins or an unstable RNA transcript. The Lor population of Khuzestan province is characterized by marriage at a young age, large family sizes and customary consanguineous marriages. Moreover, in this area, as a previous report has shown the high frequency of α1 and α2-globin mutations,6 it is expected that novel mutations will be identified with high frequency.1 In conclusion, α2 cd127 are new mutations which cause no severe hematological abnormalities among these carriers, but they lead to unstable and truncated protein or an unstable RNA transcript. Hence, we recommend the screening of non-deletional mutations after the most common deletions were discarded and this mutation should be detected in couples at risk for α-thalassemia.
**Reference**


---

**Table 1.** The hematological parameters for α-thalassemia genotype in carrier individuals

<table>
<thead>
<tr>
<th>Subject</th>
<th>Three male persons</th>
<th>One female person</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (g/dl)</td>
<td>14.56 ± 0.92</td>
<td>13.5</td>
</tr>
<tr>
<td>RBC (10^12/L)</td>
<td>6.03 ± 0.31</td>
<td>5.9</td>
</tr>
<tr>
<td>MCV(fl)</td>
<td>73.36 ± 1.96</td>
<td>74</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>24.0 ± 0.36</td>
<td>22.9</td>
</tr>
<tr>
<td>Hb A2 (%)</td>
<td>2.4 ± 0.5</td>
<td>1.9</td>
</tr>
<tr>
<td>β-genotype</td>
<td>N/N</td>
<td>N/N</td>
</tr>
<tr>
<td>α-genotype</td>
<td>α^CD 127(AAG&gt;TAG) α/αα</td>
<td>α^CD 127(AAG&gt;TAG) α/αα</td>
</tr>
</tbody>
</table>

---

**Figure 1.** Sequencing of the α-globin gene